Neuroinflammation modulation therapy represents a critical frontier in neurodegenerative disease treatment, focusing on the dysregulated immune response that contributes to neuronal dysfunction and death. Two particularly promising biomarker targets are Glial Fibrillary Acidic Protein (GFAP) and soluble Triggering Receptor Expressed on Myeloid Cells 2 (sTREM2), which serve as direct measures of astroglial and microglial activation respectively. This therapy approach aims to restore immune homeostasis while preserving the protective functions of neuroinflammation.
Neuroinflammation in Alzheimer's disease (AD) and Parkinson's disease (PD) exhibits a dual character:
- Acute protective response: Microglia and astrocytes initially respond to pathology by clearing aggregates and releasing neurotrophic factors
- Chronic harmful state: Prolonged activation leads to toxic cytokine release, oxidative stress, and secondary neuronal damage
¶ Role of GFAP and sTREM2
- GFAP: Intermediate filament protein specific to astrocytes; elevated levels indicate reactive astrocytosis
- sTREM2: Soluble fragment of microglial TREM2; reflects microglial activation status and function
Approach: Enhance TREM2 signaling to promote beneficial microglial phenotypes
- Mechanism: TREM2 activation drives microglial phagocytosis of amyloid and tau aggregates
- Therapeutic agents: TREM2 agonistic antibodies, small molecule agonists
- Biomarker target: Modulate sTREM2 levels toward healthy baseline; reduce inflammatory cytokines
- Expected biomarker response: Normalization of sTREM2 (decrease if elevated, increase if deficient)
Approach: Block excessive TREM2 signaling in over-activated microglia
- Mechanism: Prevent excessive cytokine release and reactive oxygen species
- Therapeutic agents: TREM2 blocking antibodies, decoy receptors
- Biomarker target: Reduce sTREM2 to normal range; decrease IL-1β, TNF-α
Approach: Modulate astrocyte reactivity to restore homeostasis
- Mechanism: Target GFAP-expressing reactive astrocytes
- Therapeutic agents: GFAP-targeted antibodies, cytokine modulators
- Biomarker target: Reduce GFAP levels toward normal
- Expected biomarker response: 30-50% reduction in plasma GFAP
Approach: General suppression of harmful neuroinflammation
- Examples: NSAID repurposing, minocycline, colchicine
- Limitations: Lack of specificity, side effects from systemic immunosuppression
- Biomarker monitoring: GFAP, sTREM2, inflammatory cytokines
| Disease State |
Baseline GFAP |
Treatment Goal |
Expected Reduction |
| Alzheimer's Disease |
Elevated |
Normalize |
30-50% |
| Parkinson's Disease |
Elevated |
Reduce |
20-40% |
| CBS/PSP |
Elevated |
Reduce |
25-45% |
| Disease State |
Baseline sTREM2 |
Treatment Goal |
Expected Change |
| Alzheimer's Disease |
Variable |
Modulate toward healthy |
±20-30% |
| Preclinical AD |
Normal-high |
Maintain |
Stability |
| Parkinson's Disease |
Elevated |
Reduce |
20-35% |
| Biomarker |
Sample Type |
Frequency |
Therapeutic Relevance |
| GFAP |
Plasma |
Monthly |
Astrocyte activation |
| sTREM2 |
CSF |
Quarterly |
Microglial activation |
| NfL |
Plasma |
Monthly |
Neuroaxonal injury |
| YKL-40 |
CSF |
Quarterly |
Chronic inflammation |
| IL-6 |
Plasma |
Monthly |
Systemic inflammation |
| TNF-α |
Plasma |
Monthly |
Pro-inflammatory status |
| Drug |
Target |
Phase |
Biomarker Endpoints |
| AL002 (Alector) |
TREM2 agonist |
Phase 2 |
CSF sTREM2, GFAP, NfL |
| AL003 |
TREM2 agonist |
Phase 1 |
sTREM2, inflammatory markers |
| JNJ-63743257 |
Anti-tau/sTREM2 |
Phase 1 |
CSF sTREM2, p-tau |
| GV-971 |
Gut-brain inflammation |
Phase 3 |
GFAP, inflammatory cytokines |
| Dapagliflozin |
Neuroinflammation |
Phase 2 |
GFAP, NfL |
- GFAP-positive enrichment: Select patients with elevated GFAP indicating active astrocytosis
- sTREM2 stratification: Match patients to agonist or antagonist based on baseline sTREM2
- Combinatorial biomarker panels: Use GFAP × sTREM2 ratios to identify optimal responders
- Concept: Shift microglia from disease-associated (DAM) to homeostatic phenotype
- Target: TREM2, CD33, apolipoprotein E pathways
- Biomarker readouts: sTREM2 normalization, decreased inflammatory cytokines
- Concept: Reduce reactive astrocytosis while preserving protective functions
- Target: GFAP, AQP4 water channels
- Biomarker readouts: Plasma GFAP reduction, improved neuronal function markers
- Concept: Modulate peripheral immune cell trafficking to CNS
- Target: CCL2/CCR2, CX3CL1/CX3CR1 pathways
- Biomarker readouts: CSF immune cell counts, cytokines
- Concept: Improve clearance of inflammatory mediators via glymphatic system
- Target: Sleep-dependent clearance, AQP4 polarization
- Biomarker readouts: GFAP reduction, improved sleep architecture
- Rationale: Amyloid drives neuroinflammation; treating both may be synergistic
- Example: Lecanemab + TREM2 agonist
- Biomarker panel: Aβ42, p-tau217, GFAP, sTREM2
- Rationale: Tau pathology and neuroinflammation form a vicious cycle
- Example: Anti-tau antibody + GFAP modulator
- Biomarker panel: p-tau181, GFAP, sTREM2
- Rationale: Address both neuroinflammation and neurotransmitter deficits
- Example: Anti-inflammatory + acetylcholinesterase inhibitor
- Biomarker panel: GFAP, cognitive measures
Complete response:
- GFAP normalized (within 1 SD of healthy mean)
- sTREM2 normalized
- NfL stabilized or reduced
- Clinical stabilization
Partial response:
- GFAP reduced 30-50%
- sTREM2 modulated toward healthy range
- NfL trajectory flattened
Non-response:
- No significant change in GFAP or sTREM2
- Continued NfL elevation
¶ Challenges and Future Directions
- TREM2 biology complexity: Both agonism and antagonism have theoretical benefits
- Biomarker interpretation: Optimal sTREM2 levels remain unclear
- Blood-brain barrier: Many anti-inflammatory agents have limited CNS penetration
- sTREM1: Additional microglial activation marker
- TREM2 CSF/serum ratio: May indicate TREM2 processing abnormalities
- GFAP isoforms: May provide disease-specific signatures